In this paper we discuss emergent cross-cutting themes across a series of educational intervention projects in which practitioners-in-training adopted and adapted in their proposals and work design the logic of ethnographic experimental collaboration (XCOL) and participatory action research (PAR) (Clark, 2010; Estalella & Sánchez-Criado, 2018) perspectives. We were involved in three interventions developed in Madrid (Spain) across formal and informal learning contexts as part of the internship/practicum of future educational psychologists. Our work was designed in response to the identified needs and demands of the internship sites. Yet, as educational interventions, they were explicitly conceptualized and implemented in ways that depart substantially from the common expectations of process-product educational intervention and dominant ways, at least in Spain, of constructing educational accountability (cf. Berliner, 1989; Gage & Needels, 1989). We unpack four themes relevant across the three projects, which emerged from our joint discussions of the three interventions: (a) how "outcomes/results" are reconstructed in XCOL/PAR educational interventions, (b) the transformations in our emergent professional identities, (c) the place of different materialities and expressive media in the work we planned (d) how space-time constraints were construed in our unfolding projects.

ResumenIntroducción: la tuberculosis (TB) es una complicación frecuente del uso de fármacos anti-TNFa. Ocurre por reactivación de una infección latente o por progresión de una infección reciente.Objetivos: conocer la incidencia de TB en la población que recibió fármacos anti-TNFa, analizar las formas de presentación y la realización de pesquisa de infección latente previo al inicio del tratamiento.Método: estudio de cohorte retrospectiva. Se incluyeron los pacientes que recibieron fármacos anti-TNFa entre 2010 y 2016. Los datos se obtuvieron de los sistemas informáticos del Fondo Nacional de Recursos y del Programa Nacional de Tuberculosis. Se calculó la incidencia de TB y se describieron los casos que desarrollaron TB.Resultados: se incluyeron 991 tratamientos para un total de 980 pacientes. Se reportaron nueve casos de TB. La incidencia global fue de 419,9 (IC 95% 191,,2) por 100.000 personas/año. Solo hubo casos de TB en pacientes tratados con adalimumab. El cribado de infección tuberculosa latente (ITBL) previo al inicio del fármaco fue heterogéneo y predominaron las formas de TB diseminadas (6/9) sobre la afectación pulmonar aislada (3/9). En todos los casos se suspendió el anti-TNFa al diagnóstico de TB y en ningún caso se retomó.Conclusiones: la incidencia de TB en la población de pacientes bajo tratamiento con anti-TNFa fue 16,5 veces mayor que en la población general. Predominaron las formas de TB diseminadas y se dieron casos en sujetos que habían recibido tratamiento de ITBL previo al inicio del fármaco, sugiriendo que el riesgo persiste mientras exista exposición a éste.

variables between the smoking and non-smoking categories. Results: Of the 73 patients included in the study, 54.8% were non-smokers, 50.7% were female, and 79.5% were elderly. The median VD concentration was 25.3ng / dL (17.65-32.1) and 27.2ng / dL (19-32.2) for non-smokers and 23ng / dL (16.2-32.9) for smokers. 65.8% of the sample had a VD deficiency according to criteria for risk groups, although we did not find differences between smokers and nonsmokers (p¼0.18). The median time of sun exposure was 15.7min / day and 13.83min / day for non-smokers and smokers respectively and there were no differences among them (p ¼ 0.85). Conclusion: We observed a higher proportion of individuals with VD deficiency in advanced stage lung adenocarcinoma in a sample predominantly of elderly individuals, with a history of low solar exposure prior to diagnosis in a country that presents adequate latitude for sun exposure throughout the year.

BackgroundPatients diagnosed with stage 4 non-small cell lung cancer (NSCLC) have poor survival (median 9–12 months). A platinum based regimen is generally preferred, usually with limited results. Secondline therapies have not shown long lasting responses. Nivolumab is an anti-programmed cell death 1 (PD-1) monoclonal antibody that works as a checkpoint inhibitor by improving the immune response. It is administered every 14 days in a 3 mg/kg dose. Nivolumab is the first drug that has demonstrated superior response versus docetaxel, the standard treatment for disease progression.PurposeTo evaluate survival rates and tolerability of nivolumab in NSCLC.Material and methodsA retrospective observational study was carried out from June 2015 to September 2016. Electronic medical records were reviewed and analysed using SPSS Statistics programme. Variables collected were age, sex, stage, Eastern Cooperative Oncology Group (ECOG) performance status score, subtype of NSCLC, sites of metastasis, previous lines of treatment, adverse events, progression free survival (PFS) and overall survival (OS).Results22 stage 4 patients were included (14 men, 8 women) with a median age of 64 years (51–82). ECOG0: 1 patient, ECOG1: 16 patients, ECOG2: 5 patients. Histology: 15 patients adenocarcinoma, 5 squamous cell carcinoma and 2 unknown. The most frequent metastatic sites were: liver (6), kidney (6), peritoneum (5), bone (5) and nervous system (4). Nivolumab was mostly used as a fourthline therapy (2nd–6th). Firstline was a platinum based therapy (with pemetrexed, gemcitabine or vinorelbine) in 18 patients, erlotinib in 2, and 2 patients had monotherapy with paclitaxel and gemcitabine. Docetaxel was most frequent secondline treatment. Median PFS was 1.8 months (95% CI 0.53–3.06) and median OS was 5.9 months (95% CI 0.24–11.56; 40.9% censored). The most common adverse effect was asthenia in 12 patients, followed by shortness of breath in 7. Related to immune mediated events, 2 patients had thyroid dysfunction. Grade 3–4 reactions were not detected.ConclusionThe PFS and OS results were worse than in a pivotal study (squamous cell indication, only 23% of our cases). Nevertheless, we had a small number of patients with ECOG2 (23%), and 77% used nivolumab as thirdline or more treatment, where the evidence is limited. Nivolumab was well tolerated and there was no need for treatment discontinuation.No conflict of interest

No abstract